Immunology line includes cytokine ELISA kits, cytokine ELISA construction kits, recombinant cytokines, growth factors, monoclonal and polyclonal antibodies, cytokines and CD markers, and matched antibody pairs. Custom immunological services are now available.
Alexis Biochemicals offers over 240 enzymes, antibodies, inhibitors, assay kits, and other products for studying the role of caspases in apoptosis and inflammation.
The Adipogenesis Assay Kit provides a convenient format for the induction and analysis of adipogenesis in the classic 3T3-L1 model. The most commonly used inducers of adipogenesis dexamethasone, IBMX, and insulin are provided in ready-to-use formulations.
Histone acetyltransferases (HATs) play a crucial role in a variety of cellular functions such as gene transcription, differentiation, and proliferation. This HAT assay kit utilizes active recombinant HAT protein as a positive control and acetyl-CoA as a cofactor.
Epidermal Growth Factor receptor (EGFr) 170 kDa membrane protein is expressed in many normal epithelial tissues, particularly in the basal layers of stratified or pseudostratified and squamous epitheliums.
LiquiChip bead-based xMAP assay kits facilitate research in drug discovery, cell signaling, oncogenesis, apoptosis, and immune disorders. Optimized immobilized substrates enable detection of a wide range of Tyr and Ser/Thr kinase activities without the need for radioactivity.
Bioactive hGH ELISA, for the measurement of biologically active human growth hormone, detects monomeric GH isoforms that possess both receptor binding sites, and thus is capable of receptor dimerization.
HSP27 [pS82] phosphoELISA is sensitive to 1,000 cells/well, demonstrated with HeLa cell lysates. Additional validated cell lines include THP-1, HT1080, Jurkat and 293 cells.
HDAC8 Colorimetric/Fluorometric Activity Assay/Drug Discovery Kit is HTS-friendly assay and allows real-time monitoring of HDAC activity. This is made possible by HDAC-TRAC substrate and buffer, which also enables a choice of either colorimetric or fluorometric detection.
By Catherine Shaffer The preclinical phase of drug development is a large portion of the total expense of research and development, with much of this effort focused on generating new chemical compounds and screening them for activity against disease targets. Bayer Healthcare, Leverkusen, Germany, has adopted a new informatics software system to help manage these millions of compounds.
By Catherine Shaffer A new pharmacogenetic study of cholesterol-lowering statin drugs could lead to better treatment for millions of patients. A collaboration among Harvard Medical School, Brigham and Women's Hospital, both in Boston, and the defunct Variagenics Inc., formerly of Cambridge, Mass., published in the June 16 issue of the Journal of the American Medical Association (JAMA)
By Don Monroe Celera Diagnostics (CD), Alameda, Calif., disclosed two more genetic markers that it says are associated with heart-attack risk in caucasians. Although the work is still in an early stage, this type of marker "could be useful in identifying people who should be on statins, or other cholesterol-lowering agents, who otherwise might not be candidates," says Thomas White, chief scientific officer at the company.
By Catherine Shaffer The use of gene therapy in the treatment of brain cancer is hindered by drug delivery problems. Large molecules such as monoclonal antibodies and viral vectors cannot cross the blood-brain barrier. A featured article in the June 1 issue of Clinical Cancer Research now describes the successful delivery of a nonviral RNAi gene therapy to brain tumors in mice, resulting in a significant increase in survival times.
By Mark Terry Researchers with Proteome Sciences Plc., Cobham, UK, recently identified 12 additional phosphorylation sites on the tau protein. Twenty-five phosphorylation sites had previously been identified on tau, which has been implicated in Alzheimer's disease (AD). Neurofibrillary tangles develop from a hyperphosphorylated form of the tau protein, and these are hypothesized to be the cause of neuronal cell death. By using a proprietary mass...
By Don Monroe Vertex Pharmaceuticals Inc., Cambridge, Mass., will get roughly $21 million through 2005 to continue its late-stage drug discovery collaboration with Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the company announced on May 24.